ConductScience.org, home

Comparison · NCT04222088-sae

Artemether-lumefantrine (Coartem™) + Primaquine vs Chloroquine + Primaquine: serious adverse events

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

2 sourcestrial-comparisons-2026-03-23-0.1.0

Download JSON
Cite this record

ConductScience Library. Artemether-lumefantrine (Coartem™) + Primaquine vs Chloroquine + Primaquine: serious adverse events. Trial comparisons, record NCT04222088-sae. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT04222088-sae

On this page

Measures6

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

MeasureValue95% interval, lower95% interval, upperMethodNote
Risk in group 1000.0437wilson
Risk in group 200.000000000000000003470.0487wilson
Risk difference, group 1 minus group 20-0.04870.0437newcombe hybrid score
Risk ratio, group 1 over group 2loga group has no participants with the outcome
Odds ratio, group 1 over group 2loga cell of the two-by-two table is zero
Number needed to harmfrom the risk difference intervalthe two groups' risks are equal

Groups2

Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.

GroupTitleDescriptionWith the outcomeAnalysedClinicalTrials.gov code
Group 1Artemether-lumefantrine (Coartem™) + Primaquine
Administered to patients with mono-infection of Plasmodium falciparum with 1000-100 000 asexual forms per µl. Coartem™: 20/120 mg per tablet was administered 3 days (Days 0, 1 and 2) according to body weight. For patients with weight of 5 to \<15kg, 15 to \<25kg, 25 to \<35kg, or ≥35kg, tablets of 1, 2, 3, or 4 will be given respectively. At day 3, primaquine at 0.75 mg base/kg body weight single dose will be given.
084EG000
Group 2Chloroquine + Primaquine
Administered to patients with mono-infection of Plasmodium vivax with parasite count of ≥ 250 per µl, Chloroquine 150 mg base tablet was administered according to body weight at a total dose of 25 mg/kg over 3 days (10 mg/kg on Day 0; 10 mg/kg on Day 1 and 5 mg/kg on Day 2). After 28 days of follow-up, primaquine will be given for 14 days.
075EG001

Harm

What it counts
Total, serious adverse events
Time frame

Source ClinicalTrials.gov

Trial

Title
TES of Artemether-lumefantrine for Pf and Chloroquine for Pv in the Philippines From 2013-2014
NCT number
NCT04222088
Phases
Conditions
Malaria, Falciparum Malaria, Vivax Malaria, Malaria Recrudescence
Interventions
Arthemeter-lumefantrine, Chloroquine, Primaquine
Lead sponsor
Research Institute for Tropical Medicine, Philippines
Results first posted
2023-02-23

Source ClinicalTrials.gov

Source

Release
trial-comparisons-2026-03-23-0.1.0
Release manifest SHA-256
f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
AACT copy
2026-03-23
Tables read
outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet

Source ClinicalTrials.gov

Sources 2

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.

For software

Read this comparison from software.

The record is JSON. No key.

GET https://conductscience.org/api/comparisons/v1/NCT04222088-sae